Immunotherapy for non-small cell lung cancer.

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Immune checkpoint inhibitors (ICI) target PD-1/PD-L1 and CTLA-4 pathways to enhance T-cell anti-tumor activity.
• ICI are approved for numerous cancers, with expanding indications and demonstrated efficacy across various disease stages, including early-stage lung cancer.
• Lung cancer treatment has seen significant advancements with ICI, offering durable responses and survival benefits surpassing traditional chemotherapy.

Purpose of the Study:

• To review the current landscape of ICI therapy in lung cancer.
• To discuss the historical development and future directions of ICI treatment for lung cancer.
• To highlight the need for predictive biomarkers to optimize ICI efficacy in lung cancer patients.

Main Methods:

• Review of clinical trial data and basic science evidence on ICI in lung cancer.
• Analysis of the mechanisms of action for PD-1/PD-L1 and CTLA-4 inhibitors.
• Examination of treatment outcomes and challenges in current ICI therapy.

Main Results:

• ICI have revolutionized lung cancer treatment, providing unprecedented long-term benefits.
• Significant variability in patient response to ICI therapy exists.
• Lack of reliable biomarkers for predicting ICI efficacy poses a major clinical challenge.

Conclusions:

• ICI represent a paradigm shift in lung cancer treatment, offering substantial survival advantages.
• Further research is crucial to identify biomarkers that predict response and guide personalized ICI therapy.
• The future of ICI in lung cancer involves refining treatment strategies and overcoming current limitations.